238 related articles for article (PubMed ID: 37356080)
1. Value for Money of CAR-T Cell Therapy for Patients with Diffuse Large B-cell Lymphoma in China: Evidence from a Cost-Effectiveness Analysis.
Wu W; Zhou Y; Wang Y; Keramat SA; Balasooriya NN; Zhao Z; Yang Y; Comans T; Dong H
Appl Health Econ Health Policy; 2023 Sep; 21(5):773-783. PubMed ID: 37356080
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care.
Cummings Joyner AK; Snider JT; Wade SW; Wang ST; Buessing MG; Johnson S; Gergis U
Adv Ther; 2022 Aug; 39(8):3560-3577. PubMed ID: 35689726
[TBL] [Abstract][Full Text] [Related]
3. Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma : A Cost-Effectiveness Analysis.
Kelkar AH; Cliff ERS; Jacobson CA; Abel GA; Dijk SW; Krijkamp EM; Redd R; Zurko JC; Hamadani M; Hunink MGM; Cutler C
Ann Intern Med; 2023 Dec; 176(12):1625-1637. PubMed ID: 38048587
[TBL] [Abstract][Full Text] [Related]
4. Axicabtagene ciloleucel compared to standard of care in Swedish patients with large B-cell lymphoma: a cost-effectiveness analysis of the ZUMA-7 trial.
Loftager ASL; Danø A; Eklund O; Vadgama S; Hedlof Kanje V; Munk E
J Med Econ; 2023; 26(1):1303-1317. PubMed ID: 37725082
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for the treatment of 3L + relapsed/refractory large B-cell lymphoma in the United States: incorporating longer survival results.
Oluwole OO; Ray MD; Davies N; Bradford R; Jones C; Patel AR; Locke FL
J Med Econ; 2024; 27(1):230-239. PubMed ID: 38240256
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Choe JH; Abdel-Azim H; Padula WV; Abou-El-Enein M
JAMA Netw Open; 2022 Dec; 5(12):e2245956. PubMed ID: 36520440
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US.
Oluwole OO; Liu R; Diakite I; Feng C; Patel A; Nourhussein I; Snider JT; Locke FL
J Med Econ; 2022; 25(1):541-551. PubMed ID: 35443867
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States.
Parker C; Liu FF; Deger KA; Franco-Villalobos C; Proskorovsky I; Keating SJ; Sorensen S
Adv Ther; 2023 May; 40(5):2355-2374. PubMed ID: 36947328
[TBL] [Abstract][Full Text] [Related]
9. The Cost-Effectiveness of Axicabtagene Ciloleucel as Second-Line Therapy in Patients with Large B-Cell Lymphoma in the United States: An Economic Evaluation of the ZUMA-7 Trial.
Perales MA; Kuruvilla J; Snider JT; Vadgama S; Blissett R; El-Moustaid F; Smith NJ; Patel AR; Johnston PB
Transplant Cell Ther; 2022 Nov; 28(11):750.e1-750.e6. PubMed ID: 35970302
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma.
Kambhampati S; Saumoy M; Schneider Y; Serrao S; Solaimani P; Budde LE; Mei MG; Popplewell LL; Siddiqi T; Zain J; Forman SJ; Kwak LW; Rosen ST; Danilov AV; Herrera AF; Thiruvengadam NR
Blood; 2022 Nov; 140(19):2024-2036. PubMed ID: 35914220
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of axicabtagene ciloleucel as a second-line treatment for diffuse large B-cell lymphoma in China and the United States.
Li N; Lei J; Zhang J; Cai H; Zheng B; Yang T; Liu M; Hu J
Ther Adv Hematol; 2023; 14():20406207231168215. PubMed ID: 37250912
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of axicabtagene ciloleucel vs. salvage chemotherapy for relapsed or refractory adult diffuse large B-cell lymphoma in China.
Li N; Zheng B; Cai H; Yang T; Hong Y; Liu M; Hu J
Support Care Cancer; 2022 Jul; 30(7):6113-6121. PubMed ID: 35419735
[TBL] [Abstract][Full Text] [Related]
13. A Model to Estimate Cytokine Release Syndrome and Neurological Event Management Costs Associated With CAR T-Cell Therapy.
Badaracco J; Gitlin M; Keating SJ
Transplant Cell Ther; 2023 Jan; 29(1):59.e1-59.e6. PubMed ID: 36272529
[TBL] [Abstract][Full Text] [Related]
14. An updated cost-effectiveness analysis of axicabtagene ciloleucel in second-line large B-cell lymphoma patients in the United States.
Oluwole OO; Patel AR; Vadgama S; Smith NJ; Blissett R; Feng C; Dickinson M; Johnston PB; Perales MA
J Med Econ; 2024; 27(1):77-83. PubMed ID: 38053517
[TBL] [Abstract][Full Text] [Related]
15. Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma.
Lin JK; Muffly LS; Spinner MA; Barnes JI; Owens DK; Goldhaber-Fiebert JD
J Clin Oncol; 2019 Aug; 37(24):2105-2119. PubMed ID: 31157579
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of transplant-ineligible relapsed or refractory diffuse large B-cell lymphoma treatment options-Experience of the efficiency frontier approach.
Kurte MS; Siefen AC; Jakobs F; von Tresckow B; Reinhardt HC; Kron F
Eur J Haematol; 2023 Dec; 111(6):895-908. PubMed ID: 37644352
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States.
Liu R; Oluwole OO; Diakite I; Botteman MF; Snider JT; Locke FL
J Med Econ; 2021; 24(1):458-468. PubMed ID: 33691581
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphoma.
Choe JH; Yu T; Abramson JS; Abou-El-Enein M
Blood Adv; 2024 Jan; 8(2):484-496. PubMed ID: 38153350
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis 3L of axicabtagene ciloleucel vs tisagenlecleucel and lisocabtagene maraleucel in Japan.
Tsutsué S; Makita S; Asou H; Matsuda H; Yamaura R; Taylor TD
Future Oncol; 2024 Apr; ():. PubMed ID: 38597742
[No Abstract] [Full Text] [Related]
20. Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for Treatment of Patients With Intermediate- to High-Risk Diffuse Large B-Cell Lymphoma.
Vijenthira A; Kuruvilla J; Crump M; Jain M; Prica A
J Clin Oncol; 2023 Mar; 41(8):1577-1589. PubMed ID: 36315922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
